Eli Lilly signed agreements to acquire three private vaccine companies for nearly $4 billion.
The deal includes the acquisition of Curevo, LimmaTech Biologics, and Vaccine Company.
This expansion diversifies Lilly’s portfolio beyond its successful Mounjaro and Zepbound obesity treatments.
Lilly gains access to Curevo’s clinical-stage vaccine for shingles.
LimmaTech and Vaccine Company provide programs for Epstein-Barr and antibiotic-resistant infections.
The move leverages Lilly’s manufacturing scale to build new revenue streams in disease prevention.